Quantbot Technologies LP Acquires Shares of 19,704 Pacira BioSciences, Inc. $PCRX

Quantbot Technologies LP acquired a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 19,704 shares of the company’s stock, valued at approximately $500,000.

Several other institutional investors have also recently made changes to their positions in PCRX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Pacira BioSciences by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,242 shares of the company’s stock valued at $677,000 after purchasing an additional 1,165 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Pacira BioSciences by 49.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock valued at $27,454,000 after buying an additional 367,869 shares during the last quarter. Strs Ohio purchased a new position in shares of Pacira BioSciences during the 1st quarter valued at about $75,000. Marshall Wace LLP acquired a new position in shares of Pacira BioSciences in the 2nd quarter valued at about $4,550,000. Finally, Sei Investments Co. lifted its holdings in shares of Pacira BioSciences by 35.3% in the 2nd quarter. Sei Investments Co. now owns 25,357 shares of the company’s stock valued at $606,000 after buying an additional 6,609 shares during the period. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Price Performance

Shares of NASDAQ PCRX opened at $25.83 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.94 and a current ratio of 5.04. The firm has a fifty day moving average of $25.12 and a 200 day moving average of $23.82. The firm has a market cap of $1.03 billion, a PE ratio of 73.80 and a beta of 0.27. Pacira BioSciences, Inc. has a one year low of $18.80 and a one year high of $27.66.

Pacira BioSciences (NASDAQ:PCRX) last announced its earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.08. The business had revenue of $192.40 million for the quarter, compared to analyst estimates of $191.06 million. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.74 earnings per share. As a group, research analysts predict that Pacira BioSciences, Inc. will post 1.98 EPS for the current fiscal year.

Insider Transactions at Pacira BioSciences

In other Pacira BioSciences news, insider Jonathan Slonin sold 3,040 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $23.23, for a total transaction of $70,619.20. Following the completion of the sale, the insider directly owned 216,384 shares in the company, valued at approximately $5,026,600.32. The trade was a 1.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Lauren Riker sold 6,115 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $23.50, for a total value of $143,702.50. Following the transaction, the senior vice president directly owned 62,284 shares of the company’s stock, valued at $1,463,674. The trade was a 8.94% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.40% of the company’s stock.

Wall Street Analyst Weigh In

PCRX has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Pacira BioSciences in a report on Monday, August 17th. HC Wainwright reissued a “buy” rating and issued a $38.00 price target on shares of Pacira BioSciences in a report on Wednesday, July 1st. Royal Bank Of Canada upped their price objective on Pacira BioSciences from $24.00 to $25.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 5th. Truist Financial started coverage on shares of Pacira BioSciences in a research note on Monday, August 17th. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Wall Street Zen cut shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 16th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $30.20.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.